Key result
Selective I1-imidazoline-receptor agonists provide long-term blood pressure control, favorable metabolic effects, and organ protection with fewer side effects than older sympatholytic agents.
Why the study?
Do selective I1-imidazoline-receptor agonists improve blood pressure control and metabolic outcomes in patients with hypertension?
Do selective I1-imidazoline-receptor agonists improve blood pressure control and metabolic outcomes in patients with hypertension?
Selective I1-imidazoline-receptor agonists are effective for long-term blood pressure control with added metabolic and organ-protective benefits, supporting their inclusion in Russian hypertension guidelines.
The review is devoted to selective I1-imidazoline-receptor agonists. An analysis of Russian and foreign studies is presented, the results of which indicate that this drug class not only provides adequate and long-term control of blood pressure, but also has a number of favorable metabolic effects. Therefore, it contributes to reducing insulin resistance (weight loss) and has organ protective properties (endothelial function improvement, left ventricular hypertrophy regression, microalbuminuria reduction). At the same time, selective I1-imidazoline-receptor agonists are much less likely to cause side effects characteristic of old-generation sympatholytic agents. This class of drugs is invariably included in Russian guidelines for the diagnosis and treatment of hypertension.
No takes yet. Share an insight, caveat, or question.
Небиеридзе et al. (2022) conducted a review in Hypertension. Selective I1-imidazoline-receptor agonists vs. Old-generation sympatholytic agents was evaluated. Selective I1-imidazoline-receptor agonists provide long-term blood pressure control, favorable metabolic effects, and organ protection with fewer side effects than older sympatholytic agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: